- The nation’s largest DNA bank linked to de-identified electronic health information (BioVU)
- The country’s largest academic department of biomedical informatics
- World-leading chemical biology and drug discovery programs in neuroscience and oncology
- One campus, one fully integrated culture of discovery
Genetic differences in humans at the molecular level not only contribute to the disease process but also significantly impact an individual’s ability to respond optimally to drug therapy. Vanderbilt is a pioneer in precisely identifying genetic differences between patients and making rational treatment decisions at the bedside.
Vanderbilt is home to the nation's largest DNA bank linked to de-identified electronic health information (BioVU) and the largest department of biomedical informatics. Through a cohesive set of advances it combines innovations in biomedical informatics and genomics to deliver highly personalized therapy for patients.
Our “One Vanderbilt” culture has allowed full integration of many disciplines, including its chemistry department and medical center-based target-discovery programs. This allows, as two examples among many, the broad efforts aimed at identifying key molecular causes of disease to be merged with focused efforts to identify and optimize small molecules and other compounds to become human therapies. Vanderbilt is also a leader in "derisking" drug discovery by blending academic basic research with state-of-the-art drug discovery resources; including not just the search for potential drug candidates, but also the development of molecular probes that can be used to interrogate biological function. The National Coordinating Center for the NIH CTSA and NIH eMERGE programs
Vanderbilt is a world leader in the translation of basic science to patient care, serving as the national coordinating center for all 60 NIH-supported clinical translational science (CTSA) centers conducting clinical trials of new therapies in humans. In this role, Vanderbilt is working to facilitate a wide range of multi-center clinical trials for the NIH and industry sponsors in testing new drugs and diagnostics, while advancing related health services and human factors research to enable higher quality and cost-effective health care.
- Targeted cancer drugs : Creating new ways to treat cancer without harmful side effects.
- PREDICT : Using DNA for the right dose of the right drug, the first time. PREDICT embeds genetic information in patients’ electronic medical records to guide drug choice and drug dosages. We believe Vanderbilt is the first academic medical center in the U.S. to offer this program.
- My Cancer Genome: The nation’s first personalized cancer decision support tool to help physicians and researchers track the latest developments in personalized cancer medicine and connect with clinical research trials for their patients.
- The eMERGE Network : A consortium combining DNA biorepositories with electronic medical record (EMR) systems for large-scale, high-throughput genetic research.